Holen Sie sich die Stockscreener-App
4.64
5.31%
-0.26
Handel nachbörslich:
4.67
0.03
+0.65%
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing By Investing.com - Investing.com South Africa
Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split - MarketScreener
Unicycive Therapeutics (UNCY) Announces 1-for-10 Reverse Stock S - GuruFocus
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing - Investing.com
Unicycive Therapeutics Announces Reverse Stock Split - marketscreener.com
Unicycive Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
Kaplan Fox Alerts Investors of Unicycive Therapeutics to an Investigation of Possible Securities Law Violations - FinancialContent
Equities Analysts Offer Predictions for UNCY Q3 Earnings - Defense World
Kaplan Fox is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - The Globe and Mail
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m - Yahoo Finance
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy By Investing.com - Investing.com South Africa
Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
Unicycive Therapeutics Stock: FDA Halts Progress on Key Drug - sharewise
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues - Investing.com Australia
Unicycive Therapeutics Stock Is Trading Lower Tuesday: What's Going On? - Benzinga
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues By Investing.com - Investing.com Nigeria
Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues - Endpoints News
UNCY Stock Drops Amid FDA Manufacturing Deficiencies - GuruFocus
Unicycive drops after FDA finds drug manufacturing issues - Seeking Alpha
Unicycive Says US FDA Inspection Reveals Manufacturing Deficiencies for Oxylanthanum Carbonate Drug Candidate; Shares Down - MarketScreener
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy - Investing.com Australia
Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia - marketscreener.com
Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025 - Nasdaq
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Provides Update on New Drug Application for - GlobeNewswire
FDA Manufacturing Concerns Delay Unicycive's Crucial Kidney Disease Drug Approval Process - Stock Titan
Unicycive Therapeutics reports annual meeting outcomes By Investing.com - Investing.com Canada
Unicycive Therapeutics reports annual meeting outcomes - Investing.com
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stake Boosted by Northern Trust Corp - Defense World
Unicycive Therapeutics (UNCY) Receives Buy Rating with Promising Future | UNCY Stock News - GuruFocus
PROREIT ANNOUNCES VOTING RESULTS AND EXPIRY OF RIGHTS PLAN - The Globe and Mail
JPMorgan Chase Is One of the Largest Financial Companies by Market Cap. But Is It a Buy? - The Globe and Mail
Unicycive Therapeutics (UNCY) Stock Price, News & Analysis - MarketBeat
Q2 Earnings Estimate for UNCY Issued By HC Wainwright - Defense World
Biotech Stocks Facing FDA Decision In June 2025 - RTTNews
Brokers Offer Predictions for UNCY Q4 Earnings - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Unicycive Therapeutics (UNCY): HC Wainwright & Co. Sets Price Ta - GuruFocus
Unicycive Therapeutics (UNCY): HC Wainwright & Co. Sets Price Target | UNCY Stock News - GuruFocus
Unicycive Therapeutics (UNCY) Receives Buy Rating with Promising FDA Outlook | UNCY Stock News - GuruFocus
Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences - Nasdaq
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Benchmark maintains $3 target on Unicycive stock post-Q1 filings By Investing.com - Investing.com Canada
Unicycive Therapeutics Updates Annual Meeting Time - TipRanks
Unicycive Therapeutics (UNCY) Alters 2025 Shareholder Meeting Time | UNCY Stock News - GuruFocus
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewswire
Unicycive Therapeutics Updates Annual Meeting Schedule: Key Details for Kidney Disease Biotech Investors - Stock Titan
These Numbers Show Just How Powerful Unicycive Therapeutics Inc (NASDAQ: UNCY) Stock Is - Stocksregister
Q2 Earnings Forecast for UNCY Issued By Noble Financial - Defense World
Data-Based Analysis Of Unicycive Therapeutics Inc (UNCY) - Stocksregister
Unicycive (UNCY) Advances Toward FDA Approval for Key Kidney Disease Drug | UNCY Stock News - GuruFocus
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):